A Phase 2/3 interventional study of IBI306 and IBI306 in Homozygous Familial Hypercholesterolemia, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-08-09.
Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Homozygous Familial Hypercholesterolemia with a site in China — 5 open to participants now, 6 under way, 2 of them phase 3. Homozygous Familial Hypercholesterolemia · China.
Among the 12 studies in Homozygous Familial Hypercholesterolemia with a site in China, this one is the 7th largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2019, is one of 2 in phase 2/3, and was the 3rd registered.
68 studies on the registry are indexed under Homozygous Familial Hypercholesterolemia; 13 are open to participants now.
Browse Homozygous Familial Hypercholesterolemia studies →5 of the 12 studies in Homozygous Familial Hypercholesterolemia with a site in China are open now. Recruiting first, the newest first:
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Sites in China
Ages 18+
Eddingpharm (Zhuhai) Co., Ltd. · Sites in China
Ages 18+
Novartis Pharmaceuticals · Sites in China, United States, Austria and 8 more countries
Ages 2–11
First Affiliated Hospital Xi'an Jiaotong University · Sites in China
Ages 12–55
Beijing Suncadia Pharmaceuticals Co., Ltd · Sites in China
Ages 12+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 12 Homozygous Familial Hypercholesterolemia studies recruiting now, 6 (50%) set no upper age limit and 5 (42%) stop at 75 or younger; 8 take children under 18; none take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 5
First in 2001; this study’s year is marked. 3 started in 2019.
This study's enrollment of 18 is below the median of 21 across 51 interventional studies indexed under Homozygous Familial Hypercholesterolemia.
Median enrollment 20 across the 11 interventional studies, 5 across the 1 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 12 have an industry lead sponsor. The 10 most frequent:
This study is registered under Innovent Biologics (Suzhou) Co. Ltd., one of the names counted as Innovent Biologics, Inc.. Under that name alone:
Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Innovent Biologics, Inc. has 1 study filed under Homozygous Familial Hypercholesterolemia — fewer than ten, so there is no comparison to draw.
2 of the studies in Homozygous Familial Hypercholesterolemia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06125847First Affiliated Hospital Xi'an Jiaotong UniversityNGGT006 Gene Therapy for Homozygous Familial Hypercholesterolemia | 2027-03-30 |
| NCT07591298CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Homozygous Familial Hypercholesterolemia | 2027-09-16 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Homozygous Familial Hypercholesterolemia with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A study to evaluate safety and efficacy of IBI306 in subjects with homozygous familial hypercholesterolemia.
This is a phase 2b/3 study to assess the efficacy and safety of IBI306 in subjects with homozygous familial hypercholesterolemia. Part 1 is an open-label, two-arm, multicenter pilot study to evaluate efficacy and safety of IBI306 in subjects with homozygous familial hypercholesterolemia. Part 2 is an open-label, single-arm, multicenter study to evaluate efficacy and safety of IBI306 in subjects with homozygous familial hypercholesterolemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants receive open-label IBI306 150 mg subcutaneously Q2W or 450 mg Q4W for 12 weeks.
Biological: IBI306
Participants receive open-label 450 mg Q4W subcutaneously for 12 weeks.
Biological: IBI306
Part 1: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C).
Time frame: Baseline and Week 12
Part 2: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C)
Time frame: Baseline and Week 12
Number of investigational product-related adverse events.
Time frame: Baseline and Week 12
Number of ADA and Nab.
Time frame: Baseline and Week 12
Ran from Sep 2019 to primary completion in Dec 2021, 27 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tafolecimab
Homozygous Familial Hypercholesterolemia →
Innovent Biologics (Suzhou) Co. Ltd. →